Skip to main content
Clinical Trials/NCT04980651
NCT04980651RecruitingNot Applicable

Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke: A Multicenter, Randomized, Parallel-controlled Clinical Trial

Yi Yang1 site in 1 country2,210 target enrollmentStarted: July 1, 2021Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
2,210
Locations
1
Primary Endpoint
Proportion of patients with modified Rankin Scale (mRS) Score 0-2.

Study Overview

Brief Summary

The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.

Detailed Description

In this study, 2210 cases of ischemic stroke in 72 hours were included in 10 centers in China according to the principle of random, and parallel control. The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days. The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day for 7 consecutive days. Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning in treating acute ischemic stroke.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age≥18 years, regardless of sex.
  • Patients with clinically definite diagnosis of acute ischemic stroke and able to commence RIC treatment within 72 hours of stroke onset.
  • Baseline NIHSS ≥ 4, ≤
  • Baseline mRS ≤ 2;
  • Signed and dated informed consent is obtained.

Exclusion Criteria

  • Patients who undergo thrombolytic therapy or endovascular treatment.
  • The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture, or vascular injury in the upper limb. Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc.
  • Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumors,s and other diseases involving the brain.
  • Pregnant or lactating women.
  • Previous remote ischemic conditioning therapy or similar treatment.
  • Severe hepatic and renal dysfunction.
  • Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons.
  • Unwilling to be followed up or treated for poor compliance.
  • He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission.
  • Other conditions that the researchers think are not suitable for the group.

Arms & Interventions

RIC+Standard medical treatment

Active Comparator

Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.

Intervention: Remote ischemic conditioning (Procedure)

Sham RIC+Standard medical treatment

Placebo Comparator

Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 consecutive days. Additionally, the patients will be treated with standard medical treatment according to the Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014.

Intervention: Sham remote ischemic conditioning (Procedure)

Outcomes

Primary Outcomes

Proportion of patients with modified Rankin Scale (mRS) Score 0-2.

Time Frame: 3 months

Proportion of patients with modified Rankin Scale (mRS) Score 0-2. Ranged from 0 to 6, a low value represents a better outcome.

Secondary Outcomes

  • National Institute of Health stroke scale (NIHSS) at 7 days, 30±3 days, 90±3 days from onset.(7days, 30±3 days, 90±3 days)
  • modified Rankin Scale (mRS) Score at 7 days, 30±3 days, 90±3 days from onset.(7days, 30±3 days, 90±3 days)
  • Barthel Index (BI) at 7 days, 30±3 days, 90±3 days from onset.(7days, 30±3 days, 90±3 days)
  • Proportion of patients with hemorrhagic transformation during hospitalization.(7 days)
  • Frequency of adverse events during follow-up.(90 days)

Investigators

Sponsor
Yi Yang
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Yi Yang

Associated Dean of First Hospital of Jilin University

The First Hospital of Jilin University

Study Sites (1)

Loading locations...

Similar Trials